Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|September 27, 2019

Cellink Bioprinting Platform Offers Flexibility

Cellink’s BIO X6, a six-printhead bioprinting platform, offers the capability to combine more materials, cells, and tools to enhance research applications across the bioprinting field.

BIO X6, a six-printhead bioprinting platform recently launched by Cellink, a Boston, MA-based bioprinting company, enables users to combine more materials, cells, and tools than other systems on the market, offering flexibility in bioprinting. The product, launched in September 2019, incorporates the company’s patented Clean Chamber Technology and intelligent exchangeable printhead technology. 

The BIO X6 can meet the needs of advanced tissue engineers, regenerative medicine labs, and cancer biologists that require high-throughput bioprinting and dispensing.

“Organs and tissues are comprised of many different cell types. With the BIO X6, users can combine six or more cell types to print advanced organ and tissue models. [It] gives the user freedom to combine multiple materials in one print, and the capability to create more complex architectures,” said Itedale Namro Redwan, chief scientific officer, Cellink, in a company press release. “Being able to use different pressures, temperatures, and printing methods simultaneously in six different positions is revolutionary. Users can mix the cells in each printhead with a tailored bioink, providing the cells with the biological environment they need to achieve the desired architecture.”

The system comes with a movable arm mount, enabling multiple possibilities in one system. Users can either control through a Wi-Fi connection or through a detachable tablet on the movable arm mount.

Source: Cellink


Related to this article

The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.